Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics

Eur J Nucl Med Mol Imaging. 2023 Sep;50(11):3181-3184. doi: 10.1007/s00259-023-06316-y.

Cristina Müller^{1

2}, Nicholas P van der Meulen^{3

4}, Roger Schibli^{3

5}

¹ Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, Villigen-PSI, Switzerland. cristina.mueller@psi.ch.
² Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, Zurich, Switzerland. cristina.mueller@psi.ch.
³ Center for Radiopharmaceutical Sciences ETH-PSI, Paul Scherrer Institute, Forschungsstrasse 111, Villigen-PSI, Switzerland.
⁴ Laboratory of Radiochemistry, Paul Scherrer Institute, Forschungsstrasse 111, Villigen-PSI, Switzerland.
⁵ Department of Chemistry and Applied Biosciences, ETH Zurich, Vladimir-Prelog-Weg 1-5/10, Zurich, Switzerland.

No abstract available

Publication types